Wedbush Research Analysts Reduce Earnings Estimates for YMAB

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) - Equities researchers at Wedbush dropped their Q2 2025 EPS estimates for Y-mAbs Therapeutics in a research note issued on Tuesday, May 13th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.29) per share for the quarter, down from their previous estimate of ($0.25). Wedbush currently has a "Outperform" rating and a $23.00 target price on the stock. The consensus estimate for Y-mAbs Therapeutics' current full-year earnings is ($0.65) per share. Wedbush also issued estimates for Y-mAbs Therapeutics' Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.08) EPS, Q1 2026 earnings at ($0.34) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.36) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.63) EPS and FY2028 earnings at ($1.78) EPS.

A number of other analysts also recently issued reports on the stock. Morgan Stanley dropped their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, March 5th. HC Wainwright lowered their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Monday. Truist Financial cut their target price on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Bank of America downgraded Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a research note on Tuesday, April 22nd. Finally, Oppenheimer reduced their price objective on Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a research report on Wednesday, May 14th. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $16.60.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB traded up $0.04 during trading hours on Thursday, hitting $4.21. The company's stock had a trading volume of 34,724 shares, compared to its average volume of 313,731. Y-mAbs Therapeutics has a 12 month low of $3.55 and a 12 month high of $16.11. The company's 50 day simple moving average is $4.45 and its two-hundred day simple moving average is $6.93. The company has a market cap of $190.65 million, a P/E ratio of -7.81 and a beta of 0.53.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $20.90 million for the quarter, compared to the consensus estimate of $19.97 million.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in YMAB. Brooklyn Investment Group boosted its position in shares of Y-mAbs Therapeutics by 4,563.8% in the first quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock worth $26,000 after purchasing an additional 5,796 shares during the period. KLP Kapitalforvaltning AS bought a new position in Y-mAbs Therapeutics in the 4th quarter worth $46,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Y-mAbs Therapeutics in the 1st quarter worth $49,000. Corton Capital Inc. purchased a new stake in Y-mAbs Therapeutics in the 1st quarter worth $55,000. Finally, EntryPoint Capital LLC bought a new stake in Y-mAbs Therapeutics during the first quarter valued at about $56,000. Institutional investors own 70.85% of the company's stock.

Insider Buying and Selling at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares of the company's stock, valued at $1,060,230.83. The trade was a 5.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 22.50% of the stock is currently owned by corporate insiders.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.